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Abstract
Objective—Longitudinal studies have begun to clarify the phenotypic characteristics of
adolescents and young adults at clinical high risk for psychosis. This 8-site randomized trial
examined whether a 6-month program of family psychoeducation was effective in reducing the
severity of attenuated positive and negative psychotic symptoms and enhancing functioning
among individuals at high risk.
Method—Adolescents and young adults (mean 17.4±4.1 years) with attenuated positive
psychotic symptoms, brief and intermittent psychosis, or genetic risk with functional deterioration
were randomly assigned to 18 sessions of family-focused therapy for individuals at clinical high
risk (FFT-CHR) in 6 months or 3 sessions of family psychoeducation (enhanced care, or EC).
FFT-CHR included psychoeducation about early signs of psychosis, stress management,
communication training, and problem-solving skills training, whereas EC focused on symptom
prevention. Independent evaluators assessed participants at baseline and 6 months on positive and
negative symptoms and social-role functioning.
Results—Of 129 participants, 102 (79.1%) were followed at 6 months. Participants in FFT-CHR
showed greater improvements in attenuated positive symptoms over 6 months than participants in
EC (F[1,97]=5.49, P=.02). Negative symptoms improved independently of psychosocial
treatments. Changes in psychosocial functioning depended on age: participants over 19 years
showed more role improvement in FFT-CHR, whereas participants between 16 and 19 years
showed more role improvement in EC. The results were independent of concurrent
pharmacotherapy.
Conclusion—Interventions that focus on improving family relationships may have prophylactic
efficacy in individuals at high risk for psychosis. Future studies should examine the specificity of
effects of family intervention compared to individual therapy of the same duration and frequency.
Keywords
attenuated psychotic symptoms; schizophrenia; early warning signs; psychoeducation; family
therapy
INTRODUCTION
There has been increasing interest in the role of psychosocial interventions for adolescents
and young adults who are at clinical high risk (CHR) for psychosis. Longitudinal studies
have identified phenotypic precursors to psychosis that may narrow the populations for
whom early interventions are applied, although false positive prediction rates are high.
About 35% of individuals with attenuated or intermittent psychosis symptoms, schizotypal
personality disorder, or a family history of psychosis with recent functional deterioration
develop an episode of psychosis over 2–3 years.1 A meta-analysis of 2,500 persons at
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clinical high risk in 27 studies found a conversion rate of 18% in 6 months, 22% in 1 year,
and 36% after 3 years.2
Intervening during the high-risk period may reduce subthreshold psychotic symptoms,
enhance social and role functioning, and, over the long-term, prevent or delay conversion to
episodes of psychosis. Results from early intervention trials indicate that targeted
medication strategies have short-term benefits on attenuated positive symptoms in
individuals at clinical high risk.3–7 A meta-analysis that included 4 randomized
psychotherapy trials with participants at high risk concluded that cognitive behavioral
therapy (CBT) was associated with a greater reduction in positive symptoms (standardized
mean difference = −.27) over 6–12 months compared to supportive therapy.6 The effects of
CBT and other psychosocial interventions on negative symptoms, functioning, and quality
of life were nonsignificant across studies. 6
We hypothesized that early psychosocial intervention would be strengthened by involving
family members in treatment. First, individuals at high risk for psychosis are often
adolescents living with their parents, and parental involvement may enhance the young
person’s access to mental health services. Second, the evolution of attenuated psychotic
symptoms may be affected by family contextual variables. For example, levels of expressed
emotion (i.e., criticism, hostility, or overprotectiveness) in parents were associated with the
severity of attenuated psychotic symptoms in youth at clinical high risk over 6 months.8
Levels of parental expressed emotion (EE) may escalate in reaction to the functional
deterioration of an offspring with emerging psychosis but may also become a stressor for the
offspring.9,10
This article reports results of the first multisite randomized trial of a family intervention for
youth at high risk for psychosis. We tested an adaptation of family-focused therapy (FFT), a
psychoeducational treatment found to be effective in stabilizing symptoms and delaying
recurrences among adults with bipolar I or II disorder and youth with or at high risk for
bipolar spectrum disorders.11–13 The adaptation of FFT for individuals at clinical high risk
for psychosis (FFT-CHR) emphasizes coping with stressors that may contribute to psychotic
symptoms, behavioral activation to reduce negative symptoms and increase social
engagement, and skills training to enhance interpersonal communication and problem-
solving.
This trial was conducted within the 8-site North American Prodrome Longitudinal Study, 2
(NAPLS-2).14 FFT-CHR was administered in weekly and biweekly sessions over 6 months
and compared to a brief (1 month) family educational intervention (enhanced care, or EC).
We examined two hypotheses: (1) compared to EC, FFT-CHR would be associated with
decreases in subthreshold positive symptoms (primary outcome) and negative symptoms;
and (2) FFT-CHR would be associated with greater gains in psychosocial functioning
(secondary outcome) over 6 months.
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METHOD
Participants
All 8 research centers of the NAPLS-2 consortium (Emory University, Harvard University,
University of Calgary, University of California Los Angeles, University of California San
Diego, University of North Carolina, Yale University, and Zucker Hillside Hospital)
contributed participants to the study. The study was approved by the human research review
boards of all centers.
Between January 2010 and February 2012, participants who had consented for the NAPLS-2
naturalistic study and were living with or in frequent contact with significant others (parents,
grandparents, spouses or partners) were approached by a NAPLS-2 research assistant and
invited to be evaluated for a randomized study of family intervention. Participants and at
least one relative gave written informed assent or consent to participate following a full
explanation of the procedures. Participants under age 18 signed an assent form that also
required the permission signature of their parent.
Participants met the following eligibility criteria: (1) age between 12 and 35 years; (2)
speaks and writes English, (3) meets criteria for one of three prodromal syndromes as
assessed by the Structured Interview for Prodromal Syndromes (SIPS)15 and the Scale of
Prodromal Symptoms (SOPS)16: attenuated positive symptoms with worsening in the past
year; brief intermittent psychosis; or genetic risk and deterioration, defined as a ≥ 30%
decline in Global Assessment of Functioning (GAF)17 scores in the past year, plus either a
diagnosis of schizotypal personality disorder or having a first-degree relative with psychosis.
Participants were excluded if they met current DSM-IV-TR criteria for schizophrenia or
schizoaffective disorder, pervasive developmental disorders, substance use disorders, or
neurological disorders based on the Structured Clinical Interview for DSM-IV Axis I
Disorders, Patient Version (SCID-P). 18,19
Study participants who were geographically dispersed were given the opportunity to
participate in FFT via secure videoconference; two families accepted this option. Further
information regarding recruitment strategies in NAPLS-2 can be found elsewhere. 14,20
Procedures: Outcome Assessments
Prior to the random assignments (baseline) and at 6-month follow-up, independent
evaluators (IEs) who were unaware of therapy conditions administered the SIPS interview
and rated the SOPS positive and negative symptom scales covering the prior month. IEs also
administered the SIPS/SOPS whenever a conversion event was suspected. IEs instructed
participants not to reveal their treatment assignment. The five SOPS positive symptom
scales ranged from 0 (absent) to 6 (severe and psychotic) and included unusual thought
content, suspiciousness, perceptual disturbances, grandiosity, and disorganized
communication. The six negative symptom scales included social anhedonia, avolition,
decreased emotional expressiveness, decreased experience of emotions and self, ideational
richness, and diminished role functioning. A change in one or more positive symptom items
to a score of 6 for a minimum duration (≥ 1 hr for ≥ 4 days per week in the past month) was
rated as a psychotic conversion.
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Study entry and conversion criteria were established through team consensus diagnoses from
case vignettes (see 14). Prior to the study, IEs at the 8 NAPLS-2 sites were able to reliably
distinguish subthreshold from psychotic levels of positive symptoms (K range, .80–1.0).20
During the trial, annual cross-site comparisons of total SOPS ratings with “gold standard”
SOPS ratings (intraclass correlations) ranged from 0.82–.93 among IEs across sites; for
attenuated positive symptoms, the range was .92–.96.14
At each follow-up, IEs made 100-point GAF ratings covering the prior month. They also
rated the 10-point Global Functioning-Role (GF-Role) adjustment (i.e., work or school)
scale and the Global Functioning-Social (GF-Social: i.e., romantic or peer relationship)
scale. 21
Interventions
A lead study investigator who was neither involved in the provision of treatments nor the
follow-up evaluations conducted the random assignments to FFT-CHR or EC, with 50% of
participants allocated to each condition. Allocations, performed using Efron’s biased coin
toss,22 were stratified by site and whether or not the participant was prescribed an
antipsychotic medication at baseline. Allocation results were sent by email to each site’s PI.
Drug treatment was not a requirement of the study. When participants were taking
medications (i.e., antipsychotics, antidepressants, or anxiolytics), their pharmacotherapy was
managed by a study psychiatrist, unless they wished to consult a community provider.
Psychiatrists were not told which psychosocial treatment the participant was receiving.
Physicians could adjust medication regimens or add rescue medications (e.g.,
antipsychotics) as needed during the trial, and visit frequency was allowed to vary by
physician/patient agreement.
FFT-CHR was administered to participants and parents (and when possible, siblings) in 18
1-hour family sessions (12 weekly and 6 biweekly sessions over 6 months). The objectives
of sessions 1–6 (psychoeducation) were to assist the individual at high risk and family
members to develop a personalized prevention plan summarizing stressors associated with
positive or negative symptoms, and potential coping strategies (e.g., pleasant event
scheduling, relaxation exercises). In sessions 7–12 (communication enhancement training),
participants rehearsed skills for expressing positive feelings, active listening, requesting
changes in another person’s behavior, communication clarity, and expressing negative
feelings. In sessions 13–18 (problem-solving), participants learned to break down larger
problems (e.g., “We have to stop fighting”) into smaller ones (e.g., “We need to use lower
tones of voice”), generate and evaluate solutions, and develop a solution implementation
plan. Between sessions, families were given homework assignments to encourage
generalization of the skills. (The clinicians’ manual is accessible at http://
www.semel.ucla.edu/champ/downloads-clinicians). The EC treatment consisted of 3 weekly
psychoeducational sessions in which clinicians assisted the individual at high risk and
family members to develop a personalized prevention plan.
When crises arose during the course of participation in either of the treatments, family
members or therapists scheduled individual crisis management sessions and/or the family
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was referred for emergency services. If the individual at high risk converted to psychosis,
s/he was evaluated by assessment team members and transitioned to first episode psychosis
services or local inpatient services. The participants were not withdrawn from the trial due to
conversion events.
As part of informed consent, patients were informed about alternative treatments they could
consider for prodromal symptoms and/or comorbid diagnoses (e.g., major depressive
disorder). They were allowed to participate in additional individual and/or substance abuse
treatment without being withdrawn from the trial. The independent evaluator tracked all
non-protocol treatments obtained by the participant during the 6-month trial, including any
contacts with non-study psychotherapists, counselors, or school-based personnel.
Clinician Training and Monitoring
A total of 24 clinicians from the NAPLS sites (minimum: master’s degree-level) were
trained in FFT-CHR and EC during a 2-day workshop in December 2009. During the trial,
two expert clinicians (DJM, MPO) listened to tapes of FFT-CHR or EC sessions and offered
supervision to clinicians at least once every 2 weeks. Tapes of sessions were rated for
fidelity using an adapted version of the 13-item Therapy Competence and Adherence Scales
(TCAS).23 Interrater reliability on the 13 scale items ranged from .61-.86. Supervisors
classified 90% of the FFT-CHR and EC sessions (122 ratings), drawn from all phases of
therapy, as above acceptable fidelity thresholds (ratings ≥ 5 on a 7-point scale). Clinicians
were found to be equally skillful in providing psychoeducation in both conditions, with no
differences in TCAS ratings of rapport-building, pacing of sessions, or session command. As
expected, clinicians were significantly more likely to provide communication enhancement
training (χ2(3)=17.36, p=.001) and problem solving skills training (χ2(3)=7.27, p=.03) in the
FFT-CHR than the EC sessions.24
Data Analysis
Participants in FFT-CHR and EC were compared at baseline (t-tests and X2) on sex, age,
and baseline SOPS scores (Table 1). These variables were also examined as predictors of
early study termination. The primary and secondary hypotheses were that participants in
FFT-CHR would show greater improvements in SOPS positive and negative symptoms,
respectively, from pretreatment to the 6-month reassessment than participants in EC. These
hypotheses were tested using mixed-effects regression models with a repeated measures
structure and a random subject-level intercept (PROC MIXED in SAS/STAT). 25 These
models examined the effects of time (baseline, 6 months), treatment group, and the
treatment by time interaction on scores for the 5 SOPS positive and 6 negative symptom
items. Antipsychotic treatment (prescribed or not at time of randomization) and site were
included as covariates in each model. This approach allowed subscales to be included as a
within-subject factor, to determine whether hypothesized treatment effects were general
across all positive and/or negative symptoms or specific to individual symptoms. All
analyses were by intent-to-treat. Power for the study’s repeated measure design, calculated
prior to the trial based on an expectation of 120 participants and 20% attrition, was 80% to
detect a medium-sized (0.50 SD) group difference in symptoms (alpha=.05, two-tailed).
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Exploratory mixed models were used to examine group, time, and group by time effects on
changes in psychosocial functioning (pretreatment to 6 month changes in GAF, GF-Role,
and GF-Social scores). The potentially moderating effects of sex and age were examined in
mixed models that included two-way and three-way interactions between treatment, sex/age,
and time on changes in symptoms or functioning. Because of a high degree of positive skew,
age was treated as a categorical variable: early/middle adolescence (ages 12–15 yrs), late
adolescence (ages 16–19), and young adulthood (ages 20 and older). Our study design had
95% power to detect a three-way interaction between treatment, age group, and time with a
medium effect size (f=.25) (p < .05).
RESULTS
Sample Composition
Participants were 129 adolescents and young adults (mean 17.4 ± 4.1 yrs., range 12–32;
42.6% females). Of the 129, 27 (20.9%) were taking antipsychotic medications at
randomization. None of the variables listed in Table 1 differed across the treatment groups.
Treatment and Study Completion
Rates of study withdrawal did not differ across treatments (Figure 1): 55 of 66 FFT-CHR
participants (83.3%) and 47 of 63 (74.6%) EC participants completed the baseline and 6-
month assessments (χ2(1)=1.49, p=.22). Because of its shorter duration, the mean interval
between the final therapy session and the 6-month outcome interview was longer in EC
(21.8±15.9 weeks) than in FFT-CHR (10.7±12.6 weeks).
The average number of FFT-CHR sessions was 11.0±7.1 (range 0–19), and EC sessions,
2.4±1.2 sessions (range 0–4; Table 1). Of 66 FFT-CHR participants, 42 (63.6%) were
exposed to at least one session of communication or problem-solving skills training. Of 63
EC participants, 50 (79.4%) were exposed to most or all (2–3 sessions) of the
psychoeducational content. Participants in FFT-HR were equally likely to obtain extra-
protocol individual or group therapy sessions (34.5%) as participants in EC (36.2%; χ2(1)=.
03, p=.86; Table 1). Sex, age, ethnicity, baseline GAF score, or use of antipsychotics was
not associated with completion of the study or completion of either treatment.
Positive and Negative Symptoms
There was a significant main effect of time (F[1, 97]=31.95, p<.0001) and no main effect of
treatment group (F[1,97]=.96, p=.33) on changes in total SOPS positive symptoms. There
was, however, a treatment group by time interaction on positive symptoms (F[1,97]=5.49,
p=.02), indicating greater improvement from baseline to 6 months in FFT-CHR compared to
EC (d=.56; Figure 2). Participants who were prescribed antipsychotics at baseline showed
greater improvement in attenuated positive symptoms over 6 months than those who were
not prescribed antipsychotics (F[1,97]=5.96, p=.02). There was no interaction between
psychosocial treatment, baseline antipsychotics, and time on attenuated positive symptoms
(F[1,97]=1.58, p=.21), nor were there main or moderating effects of site, sex or age (p >.10).
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A repeated measure mixed model that included the 5 SOPS items (considered
simultaneously) as within-subject variables revealed a treatment by time interaction on
changes in positive SOPS scores (F[1,986]=4.17, p=.04), but no psychosocial treatment by
SOPS item by time interaction (F[4,986]=.43, p=.79). Thus, FFT-CHR was associated with
equivalently greater improvements across all positive symptoms compared with EC.
There was a main effect of time on negative symptoms (F[1,95]=15.14, p<.0002), no effect
of psychosocial treatments (F[1,95]=.47, p=.50) and no treatment group by time interaction
(F[1,95])=.93, p=.34). However, participants who entered the trial on antipsychotics showed
greater improvement in total negative symptom scores than those not on antipsychotics
(F[1,95]=4.96, p=.03). The improvements in total negative symptom scores were not
attributable to changes in specific negative symptom items (F(5,1198)=.33, p=.90).
Inclusion in the mixed models of site, sex, age, or number of weeks between last therapy
session and the 6-month outcome assessment did not alter these results. There were no
within-group associations in either treatment condition between number of sessions attended
and improvements over 6 months in positive or negative symptoms.
Conversion to Psychosis
Of the 102 participants with baseline and 6-month SOPS data, conversions to psychosis
occurred in 6 (5.9%). None of the 6 participants who converted were taking antipsychotic
medications at entry. Conversions were observed in 5 of 47 EC participants (10.6%; mean
days to conversion = 54.6±61.1) and in 1 of 55 (1.8%) FFT-CHR participants (adjusted
OR=4.7). This participant converted within 30 days of randomization.
Psychosocial Functioning
There was a main effect of time on changes in GAF scores from baseline to 6 months
(F[1,93] =25.99, p<.0001), indicating that functioning was improving. However, there was
no interaction between treatment group (or antipsychotic group) and time on GAF scores. A
secondary analysis revealed an interaction between psychosocial treatment and time that
depended on participants’ ages (F[2,92]=5.72, p=.005) (Figure 3). Among participants who
were young adults (ages 20 or older; n=27), FFT-CHR was associated with larger pre/post
increases in GAF scores than EC (p=.04; d=1.24). However, among older adolescents (16–
19 yrs., n=51), EC was associated with greater increases in GAF scores than FFT-CHR (p< .
05; d= −.67). Younger adolescents (ages 12–15; n = 50) improved by an average of 8.9 scale
points in FFT-CHR and 3.3 points in EC, a nonsignificant difference (p=.13; d=.43).
There was a three-way interaction between treatment, age group, and time on changes in
GF–Role scores (F[2,92]=8.65, p=.0004), indicating greater improvements in role
functioning in young adults (≥ 20 yrs.) who received FFT-CHR (p=.02; d=.70). In contrast,
improvements in role functioning in adolescents (age 16–19 yrs) were greater in EC than in
FFT-CHR (p=.004; d= −.94), but there was no treatment group difference among younger
adolescents (12–15 yrs.; p=.35). GF-Social scores improved with time across all age groups
(F[1,92]=11.82, p< .001), but there was no interaction between treatment group, age, and
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time (p=.52). There were no within-group associations in either treatment condition between
number of sessions and changes in GAF or GF-Role or –Social scores.
Changes in Pharmacological Treatments
Data on medications prescribed at baseline and 6-months were available for 111 of the 129
participants (Table 2). A log-linear regression analysis indicated that participants in both
psychosocial treatments were more likely to be prescribed antipsychotics during the trial
(35.2%) than at time of randomization (20.9%) (χ2(1)=6.34, p=.01). There were no
interactions between treatment condition and time (baseline, 6 months) on prescriptions for
antipsychotics, antidepressants, anxiolytics, psychostimulants, or mood stabilizers (Table 2).
DISCUSSION
To our knowledge, this is the first randomized trial of a family intervention for individuals at
high risk for psychosis. Modern psychoeducational approaches emphasize building the
vulnerable person’s skills for managing symptoms, with family members as allies in this
process.26 FFT-CHR was associated with greater improvement in attenuated positive
symptoms over 6 months than a brief treatment (EC) oriented toward symptom prevention.
The effects did not extend to negative symptoms. Our results are similar to those of
randomized trials of CBT in individuals at high clinical risk, trials that have demonstrated
significant effects on positive but not negative symptoms.6
Prior intervention studies of populations with attenuated psychotic symptoms followed over
6-month to 1-year periods have observed low rates of conversion to psychosis (range 0% to
22%).4,27–30 In this trial, 6 of 102 (5.9%) participants developed a psychotic episode over 6
months, 5 in EC (10.6%) and one in FFT-CHR (1.8%). Future trials with longer follow-up
will be necessary to clarify whether structured family interventions (without adjunctive
medications) can affect conversion rates in individuals at clinical high risk.
The results of this trial for the primary outcome of attenuated positive symptoms can be
compared to results of a recent trial of FFT vs. brief psychoeducation on stabilizing mood
symptoms among children and adolescents at high risk for bipolar disorder.13 Over 1 year,
children and adolescents with major depression and/or subthreshold mania - all of whom had
a first-degree relative with bipolar I or II disorder - had more rapid recoveries from
depression symptoms, greater reductions in hypomanic symptoms, and more time in
remission if they received FFT than brief psychoeducation. The coping skills emphasized in
FFT, including early recognition of illness episodes, broadening skills for coping with stress,
and effective family communication and problem-solving, may be equally applicable to
emerging psychotic or bipolar disorders.
In the present study, participants in both psychosocial treatments showed significant
improvements in negative symptoms over 6 months. Although changes in negative
symptoms may be attributable to the passage of time, it is also conceivable that the
behavioral activation component of FFT-CHR and EC, in which individuals at high risk and
their family members are encouraged to increase their engagement in rewarding events, was
responsible for a portion of these changes. Adapting and testing behavioral activation
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treatments for depression in young populations at high risk for psychosis would more
directly test this hypothesis. 31
In a prior study involving a subset of participants from the current trial, individuals at high
risk and parents who received FFT-CHR showed greater increases from a pretreatment to a
6-month family interactional assessment in positive communication behaviors (e.g., active
listening) and greater decreases in conflictual behaviors (e.g., criticisms) than individuals in
EC. 32 One mechanism by which family interventions may exert their effects is through
increasing the ratio of positively- to negatively- valenced communication behaviors in
families, which may help buffer the person at high risk from other forms of environmental
stress.33
A secondary finding was that both groups of participants improved in social and role
functioning over 6 months. Participants over age 20 showed greater functional improvement
in FFT-CHR compared to EC, whereas participants between the ages of 16–19 showed
greater functional improvement in EC. The key difference in session content between the
two treatments is the emphasis on communication and problem-solving skills in FFT-
CHR.24 Increases in the individual’s use of positive communication strategies with parents
or siblings may lead to reciprocal increases in these family members’ use of constructive
communication, which may in turn increase the individual’s self-efficacy regarding
managing peer and work relationships. Young adult participants may be better able to
generalize the use of skill training to their school and work settings than adolescent
participants. In contrast, older adolescents may respond best to a brief self-management
approach that emphasizes coping with symptoms in stressful interpersonal circumstances. A
prior study showed that adolescents with bipolar disorder who reported higher levels of
stress in peer relationships showed less improvement in intensive family treatment over 12
months than those who reported low levels of peer stress.34 These findings, if replicated in
other psychosocial treatment trials of youth at clinical high risk, suggest the importance of
considering the effects of age on skill acquisition and functional recovery.
A possible interpretation of this study is that antipsychotic medications are more effective in
treating attenuated positive and negative symptoms than psychosocial treatments. However,
only a small subsample of participants (20.9%) entered the study on antipsychotic agents.
Antipsychotics were not assigned randomly; thus, participants who had previously
responded to antipsychotics may have been overrepresented in this subsample. Conducting
psychosocial treatment trials in individuals at high risk who are ineligible for or refuse
antipsychotic agents may lead to sampling biases. Instead, standardized algorithms for drug
selection or augmentation, monitoring participants’ adherence to regimens, and keeping
physicians blind to psychotherapy conditions are necessary to rule out the inter-current
effects of pharmacotherapy.
As is true of the majority of randomized trials of psychotherapy for individuals at risk for
psychosis,6 the experimental and control treatments in this trial differed in the number of
protocol sessions (18 versus 3). Thus, we cannot determine whether the greater benefits of
FFT-CHR on positive symptoms can be attributed to specific factors (i.e., its broader array
of skill training modules), differences in the length of the interval between the last treatment
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session and the 6-month assessment, or the greater frequency of therapeutic contact in FFT-
CHR and increased opportunities for clinicians to intervene early with symptom changes.
Nonetheless, studies that compare a new treatment to usual care – which usually means
comparing treatments that are not matched on number of sessions – are a critical first step in
determining whether future trials of the treatment should be pursued. Differences between
treatments in duration and therapist attention are often consistent with the way treatments
are given in practice.35 For example, families of young patients with subthreshold psychosis
would be unlikely to attend a lengthy educational program if a shorter, equally effective
alternative were available.
Another study limitation is that the 129 participants represent a small subset of the 451
NAPLS-2 participants assessed for the trial (Figure 1). Although there were a variety of
reasons that participants in NAPLS-2 did not participate in this trial, the majority of those
excluded refused or had family members who refused because of distance and time
commitments. This rate of exclusion is comparable to rates found in other studies of
psychosocial intervention for individuals at high risk for psychosis. 7,27 Nonetheless, it is
incumbent upon researchers and clinicians to develop psychosocial interventions that have a
broader reach for the intended high-risk populations. Future trials should consider the cost-
effectiveness of psychosocial interventions in individuals at high risk, especially when
requiring the involvement of family members who may incur economic or practical costs.
Briefer treatments that address immediate symptoms (e.g., anxiety reduction), perhaps
followed by booster sessions focused on preventative maintenance strategies, may decrease
the net costs of psychosocial care. Alternatives to in-person treatment, such as telehealth or
internet-based approaches, deserve further exploration in these populations.36
Despite these limitations, this study contributes to a growing body of evidence suggesting
that early psychosocial interventions benefit individuals at risk for psychosis. Contrary to
concerns regarding the possible negative impact of early intervention37, a broad range of
treatments (individual, family, group, CBT, supportive) are associated with symptomatic
improvement,6 and in this study more treatment was of greater benefit than less. Future
studies that compare family interventions to equally intensive psychosocial interventions
that have a track record in populations at risk for psychosis, such as CBT, would allow
control over therapist attention variables. Moreover, studies testing family and individual
modalities would allow the comparison of mediational pathways (e.g., improvements in
family communication versus changes in behavioral activation or attributional styles) in
stabilizing attenuated positive symptoms among vulnerable individuals.
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Clinical Guidance
• This randomized trial examined an 18-session, 6-month family-focused therapy
for 129 individuals at clinical high risk (FFT-CHR) for psychosis. Participants
were between the ages of 12 and 35 years old and had attenuated positive
symptoms with recent functional deterioration.
• FFT-CHR included psychoeducation regarding stress management and
prevention of psychosis symptoms, communication training, and problem-
solving skills training. The comparison treatment, enhanced care (EC), involved
three sessions of family psychoeducation focusing on symptom management.
• The participants in FFT-CHR had greater reductions in positive symptoms than
participants in EC over 6 months.
• The participants who were 20 years or older showed greater improvements in
psychosocial functioning (e.g., work or school performance) if they received
FFT-CHR than if they received EC, whereas those between ages 16 and 19
years old showed greater functional improvements in EC than in FFT-CHR.
• Young adults with subthreshold psychotic symptoms may benefit from family
interventions that emphasize psychoeducation and skills training.
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Figure 1.
CONsolidated Standards of Reporting Trials (CONSORT) Diagram
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Figure 2.
Effects of family-focused treatment for individuals at clinical high risk (FFT-CHR) and
enhanced care (EC) on positive symptoms over 6 months. SOPS = Scale of Prodromal
Symptoms. The values are adjusted means and standard errors from intent-to-treat mixed-
effect regression models. The treatment by time interaction was significant (F[1, 97] = 5.49,
p = .02; n=102).
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Figure 3.
Effects of family-focused treatment for individuals at clinical high risk (FFT-CHR) and
enhanced care (EC) on Global Assessment of Functioning (GAF) scores over 6 months. The
values are adjusted means and standard errors from intent-to-treat mixed-effect regression
models. The three-way interaction between treatment group, age group, and time was
significant (F[2,92]=5.72, p=.005, n=102).
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Table 1
Sample Characteristics
Variable Enhanced Care (n = 63) FFT-CHR (n = 66) Total (N = 129)
Age, mean yrs. (SD) 17.4 (3.9) 17.3 (4.2) 17.4 (4.07)
Female sex, n (%) 28 (44.4) 27 (40.1) 55 (42.6)
Years of education 10.3 (2.6) 10.3 (2.8) 10.3 (2.7)
Hispanic ethnicity, n (%) 15 (23.8) 13 (19.7) 28 (21.7)
Race, n (%)
 Caucasian 44 (69.8) 45 (68.2) 89 (69.0)
 Asian American 4 (6.3) 3 (45.5) 7 (5.4)
 African American 10 (15.9) 10 (15.2) 20 (15.5)
 Native American 1 (1.6) 2 (3.0) 3 (2.3)
 Other 4 (4.8) 6 (7.6) 10 (6.2)
Living with parents, n (%) 56 (88.9) 61 (92.4) 117 (90.7)
Prodromal Syndrome Category
 Attenuated positive symptoms 58 (92.1) 60 (90.9) 118 (91.5)
 Genetic risk and deterioration 1 (1.6) 2 (3.0) 3 (2.3)
 Brief Intermittent Psychosis 3 (4.8) 0 (0.0) 3 (2.3)
 Schizotypal personality disorder 1 (1.6) 4 (6.1) 5 (3.9)
Lifetime axis I disorder, n (%)
 Anxiety 35 (55.6) 32 (48.5) 67 (51.9)
 Mood 18 (28.6) 27 (40.9) 45 (34.9)
 Attention-deficit/hyperactivity 7 (11.1) 15 (11.6) 22 (17.1)
 Alcohol abuse/dependence 4 (6.3) 4 (6.1) 8 (6.2)
 Cannabis abuse 6 (9.5) 7 (10.6) 13 (10.1)
Global Assess. Functioning, prior mo., M (SD) 46.7 (9.2) 47.3 (9.3) 47.0 (9.2)
Protocol sessions, M (SD) 2.1 (1.2) 11.0 (7.1) 6.4 (6.6)
Received Extra-Protocol Therapy, n (%) 19 (34.5%) 17 (36.2%) 36 (35.3%)
Note: FFT-CHR = family-focused treatment for individuals at clinical high risk.
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Table 2
Medication Regimens at Time of Randomization and 6 Month Reassessment
Medication Class Assessment Point Enhanced Care (n =63) FFT-CHR (n=66)
Antipsychotic
Baseline 13 (20.6) 14 (21.2)
6 months 17 (32.7) 21 (35.6)
Antidepressant
Baseline 20 (31.8) 18 (27.3)
6 months 20 (38.5) 25 (42.4)
Psychostimulant
Baseline 5 (7.9) 7 (10.6)
6 months 7 (13.5) 9 (15.3)
Anxiolytic
Baseline 7 (11.1) 5 (7.6)
6 months 8 (15.4) 7 (11.9)
Mood stabilizer
Baseline 3 (4.8) 4 (6.1)
6 months 3 (5.8) 7 (11.9)
Note: Frequencies of medication class indicate the number of participants who were prescribed each type of medication, followed by percentages in
each treatment condition. At 6 months, medication data were available for 52 of 63 (82.5%) participants in enhanced care and 59 of 66 (89.4%)
participants in family-focused treatment for individuals at clinical high risk for psychosis (FFT-CHR).
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